MA71632A - Polynucléotides modifiés pour l'expression sélective de cellules - Google Patents

Polynucléotides modifiés pour l'expression sélective de cellules

Info

Publication number
MA71632A
MA71632A MA71632A MA71632A MA71632A MA 71632 A MA71632 A MA 71632A MA 71632 A MA71632 A MA 71632A MA 71632 A MA71632 A MA 71632A MA 71632 A MA71632 A MA 71632A
Authority
MA
Morocco
Prior art keywords
cell expression
modified polynucleotides
selective cell
selective
polynucleotides
Prior art date
Application number
MA71632A
Other languages
English (en)
Inventor
Ruchi Jain
Elizaveta A. ANDRIANOVA
Christopher Pepin
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of MA71632A publication Critical patent/MA71632A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/007Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA71632A 2022-07-25 2023-07-24 Polynucléotides modifiés pour l'expression sélective de cellules MA71632A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263391863P 2022-07-25 2022-07-25
PCT/US2023/070820 WO2024026257A2 (fr) 2022-07-25 2023-07-24 Polynucléotides modifiés pour l'expression sélective de cellules
EP23764782.1A EP4561638A2 (fr) 2022-07-25 2023-07-24 Polynucléotides modifiés pour l'expression sélective de cellules

Publications (1)

Publication Number Publication Date
MA71632A true MA71632A (fr) 2025-05-30

Family

ID=87929083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71632A MA71632A (fr) 2022-07-25 2023-07-24 Polynucléotides modifiés pour l'expression sélective de cellules

Country Status (5)

Country Link
US (1) US20260035714A1 (fr)
EP (1) EP4561638A2 (fr)
MA (1) MA71632A (fr)
TW (1) TW202417019A (fr)
WO (1) WO2024026257A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025167868A1 (fr) * 2024-02-05 2025-08-14 深圳深信生物科技有限公司 Acide nucléique modifié et son utilisation
WO2025219365A1 (fr) * 2024-04-15 2025-10-23 BioNTech SE Répression d'expression de cargaison

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2424571T3 (pl) * 2009-04-30 2020-10-19 Ospedale San Raffaele S.R.L Wektor genowy
CA3140685A1 (fr) * 2019-06-10 2020-12-17 Vijay G. Sankaran Compositions et methodes pour le traitement de la dba au moyen d'une therapie genique avec gata1

Also Published As

Publication number Publication date
WO2024026257A3 (fr) 2024-03-14
EP4561638A2 (fr) 2025-06-04
US20260035714A1 (en) 2026-02-05
TW202417019A (zh) 2024-05-01
WO2024026257A2 (fr) 2024-02-01

Similar Documents

Publication Publication Date Title
MA71632A (fr) Polynucléotides modifiés pour l'expression sélective de cellules
EP4295525A4 (fr) Mécanisme d'activation de cellules
EP1948791A4 (fr) Activation parthenogenique d'oocytes humains pour la production de cellules souches embryonnaires humaines
EP1576131A4 (fr) Motifs d'expression de cellules endotheliales cerebrales
EP1775341A4 (fr) Procédé pour induire la différenciation de cellules d'origine amniotique, et utilisation correspondante
EP4211792C0 (fr) Pilier pour suiveurs solaires
EP1989232A4 (fr) Médiation de cytotoxicité de cellules mettant en évidence l'expression superficielle de cd59
EP4420387A4 (fr) Bons critères de qualité cellulaire
EP4473144A4 (fr) Cellule d'electrolyseur
EP4265032A4 (fr) Sélection de cellule pour transmission en liaison montante
EP4274029A4 (fr) Structure d'électrode de sortie de module
EP4149496A4 (fr) Cellules t spécifiques au sars-cov-2
EP3950936A4 (fr) Composition d'additif pour milieu de culture de cellules nk, procédé de culture pour cellule nk l'utilisant, et composition cosmétique obtenue par ce procédé pour améliorer les problèmes cutanés
EP4421910A4 (fr) Électrode pour batterie tout solide
EP4183900A4 (fr) Catalyseur d'électrode pour des cellules d'électrolyse de l'eau, cellule d'électrolyse de l'eau et dispositif d'électrolyse de l'eau
EP4445213A4 (fr) Déflecteurs pour adresser individuellement de longues chaînes d'ions
EP4301771A4 (fr) Domaines extracellulaires de pd-1 mutants
EP4006148A4 (fr) Procédé de fabrication de population cellulaire contenant des cellules immunitaires d'expression de récepteur antigénique chimérique
EP3815148A4 (fr) Fabrication d'électrodes pour cellules de mémoire
EP4158001A4 (fr) Procédés pour provoquer l'expansion de cellules souches hématopoïétiques
CA3265841A1 (fr) Cellule d'électrolyse
EP4257620A4 (fr) Électrolyte sous forme de gel
EP4183903A4 (fr) Électrode de génération d'oxygène
EP3811983A4 (fr) Composition pour transplantation de cellules, et procédé de transplantation de cellules
EP1621610A4 (fr) Procede de production de cellules souches embryonnaires au moyen d'une technique de transfert de noyau de cellule somatique